Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDV/SOF + Vedroprevir +/- RBV in Treatment-Experienced HCV GT1 with Cirrhosis
NCT02226549Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vedroprevir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Jul 2014; status: completed.
02
Drugs
vedroprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02226549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02226549.